MULTICENTER SURVEY ON MANAGEMENT AND OUTCOME OF A RARE HEMATOLOGIC DISEASE: ADULT ONSET HISTIOCYTOSES.
EHA Learning Center, Davide Lazzarotto, 215649
IS ANEMIA THE MAIN SURVIVAL MARKER IN PATIENTS WITH MYELOFIBROSIS IN THE RUXOLITINIB ERA?
EHA Learning Center, María Isabel Montero, 215650
DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER EXPERIENCE OF THE RETE EMATOLOGICA LOMBARDA (IRON-M STUDY)
EHA Learning Center, Elena Maria Elli, 215651
MYELOID AND LYMPHOID NEOPLASMS ASSOCIATED WITH PDGFRA AND PDGFRB REARRANGEMENTS: CLINICAL CORRELATES AND SURVIVAL OUTCOMES.
EHA Learning Center, Abhishek Mangaonkar, 215652
ASSESSING SERUM ALBUMIN CONCENTRATION, LYMPHOCYTE COUNT AND PROGNOSTIC NUTRITIONAL INDEX MIGHT IMPROVE PROGNOSTICATION IN PATIENTS WITH MYELOFIBROSIS
EHA Learning Center, Marko Lucijanic, 215653
LONG-TERM OUTCOME OF PATIENTS WITH SPLANCHNIC VEIN THROMBOSIS AND MYELOPROLIFERATIVE NEOPLASMS: A SINGLE CENTER EXPERIENCE
EHA Learning Center, Danijela Lekovic, 215654
GENDER EFFECT ON PHENOTYPE AND GENOTYPE IN PATIENTS WITH POST-POLYCYTHEMIA VERA AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS: RESULTS FROM THE MYSEC PROJECT
EHA Learning Center, Daniela Barraco, 215655
TARGETED TREATMENT WITH DIVERSE TYROSINE KINASE INHIBITORS IN PATIENTS WITH PCM1-JAK2, BCR-JAK2 AND ETV6-ABL1 POSITIVE EOSINOPHILIA-ASSOCIATED MYELOID/LYMPHOID NEOPLASMS
EHA Learning Center, Georgia Metzgeroth, 215656
MANAGEMENT AND OUTCOME OF 25 PREGNANCIES IN WOMEN WITH POLYCYTHAEMIA VERA
EHA Learning Center, Irene Bertozzi, 215657
PEGYLATED INTERFERON ALPHA-2B VERSUS ΑLPHA-2A FOR THE TREATMENT OF ESSENTIAL THROMBOCYTHEMIA: EFFICACY AND SAFETY PROFILE.
EHA Learning Center, Novella Pugliese, 215658
LIMITATIONS OF PREVIOUS PROGNOSTIC MODELS FOR THROMBOSIS AND EXPLORATION OF MODIFIED MODELS IN PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA
EHA Learning Center, Yoshinori Hashimoto, 215659
SERVICE EVALUATION OF PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM AND SPLANCHNIC VEIN THROMBOSIS (MPN-SVT).
EHA Learning Center, Sarah Wharin, 215660
FAMILIAL MYELOPROLIFERATIVE NEOPLASMS: A SINGLE-INSTITUTION ANALYSIS OF 22 FAMILIES
EHA Learning Center, Margherita Maffioli, 215661
THROMBOEMBOLIC EVENTS AFTER DIAGNOSIS OF POLYCYTHAEMIA VERA IN A SINGLE CENTER POPULATION
EHA Learning Center, Natalia Curto-Garcia, 215662
MIPSS70 AND TRANSFUSION DEPENDENCE PREDICT SURVIVAL IN MYELOFIBROSIS PATIENTS TREATED WITH JAK1/2 INHIBITOR THERAPY
EHA Learning Center, Caroline Mcnamara, 215663
JAK2 ALLELIC RATIO PREDICT HIGHER TROMBOTIC RISK IN MYELOFIBROSIS PATIENTS. A SINGLE CENTER EXPERIENCE ON 143 PATIENTS.
EHA Learning Center, Mirko Farina, 215664
RUXOLITINIB AND HYDROXYUREA COMBINATION FOR THE TREATMENT OF MYELOFIBROSIS
EHA Learning Center, Novella Pugliese, 215665
THE “MYMPN” PATIENT REGISTRY: VALIDATION OF A PROSPECTIVE MYELOPROLIFERATIVE NEOPLASM PATIENT REGISTRY
EHA Learning Center, Robyn Scheber, 215666
THE RELATIONSHIP OF BODY MASS INDEX TO SYMPTOM BURDEN IN THE MYELOPROLIFERATIVE NEOPLASMS
EHA Learning Center, Robyn Scheber, 215667
MANAGEMENT AND OUTCOME OF PATIENTS DIAGNOSED WITH POLYCYTHEMIA VERA IN YOUNG AGE
EHA Learning Center, Giulia Bogoni, 215668
RUXOLITINIB IN MYELOFIBROSIS: A MULTICENTRE EXPERIENCE IN ENGLAND, NORTHERN IRELAND AND WALES
EHA Learning Center, James Russell, 215669
TREATMENT STRATEGIES FOR POLYCYTHEMIA VERA: OBSERVATIONS IN A DUTCH ‘REAL-WORLD’ COHORT STUDY
EHA Learning Center, Peter Westerweel, 215670
PREGNANCY OUTCOMES IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS – PALG (POLISH ADULT LEUKEMIA GROUP) A RETROSPECTIVE ANALYSIS
EHA Learning Center, Bozena Sokolowska, 215671
SECOND MALIGNANCIES IN HIDROXYUREA AND INTERFERON TREATED PATIENTS
EHA Learning Center, Telma Domingues, 215672
CORRELATIONS BETWEEN GENETIC AND CLINICAL CHARACTERISTICS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
EHA Learning Center, Liubov Polushkina, 215673
MUTATIONAL PROFILES OF CLASSIC MYELOPROLIFERATIVE NEOPLASMS IN TAIWANESE PATIENTS: FREQUENCY AND CLINICAL CORRELATION
EHA Learning Center, Huan-Chau Lin, 215674
SPLENIC MARGINAL ZONE B-CELL LYMPHOMAS DEPENDS ON PROGRAMMED DEATH-LIGAND 1 FOR CLONAL EMERGENCE AND ARE CONTROLLED BY T-CELLS FOR PROLIFERATION RATE
EHA Learning Center, Nathalie FAUMONT, 215676
MECHANISMS CONFERRING RESISTANCE TO VENETOCLAX IN CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA
EHA Learning Center, Daniela Steinbrecher, 215677
CLINICAL, PATHOLOGICAL AND MOLECULAR STUDY OF 46 PATIENTS WITH A DIAGNOSIS OF CD5-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA.
EHA Learning Center, Vincent Allain, 215678
THE NOVEL TUMOR SUPPRESSOR SAMHD1 IS FREQUENTLY DOWNREGULATED AND CORRELATES WITH GERMINAL CENTER PHENOTYPE IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
EHA Learning Center, Ioanna Xagoraris, 215679
DUAL TARGETING OF BRD4 BY AZD5153 AND BCL2 BY AZD4320 FOR HIGH-RISK B-CELL LYMPHOMAS CONCOMITANTLY OVEREXPRESSING C-MYC AND BCL2
EHA Learning Center, Junya Kuroda, 215680
INTEGRATIVE GENOME-WIDE ANALYSIS REVEALS REGULATION OF CELL PROLIFERATION INVOLVING MULTIPLE SIGNALING PATHWAYS BY BRD4-BINDING TARGET GENES IN MANTLE CELL LYMPHOMA CELL LINES.
EHA Learning Center, Taku Tsukamoto, 215681
TRANSCRIPTOME SEQUENCING IN DIFFUSE LARGE B-CELL LYMPHOMA - RIBOSOME BIOGENESIS AND DYSREGULATION OF THE ACTIN CYTOSKELETON ARE ASSOCIATED WITH IMMUNOCHEMOTHERAPY RESISTANCE
EHA Learning Center, Mimmie Stern, 215682
PD1-TIM3+ CELLS ARE THE PREDOMINANT POPULATION OF EXHAUSTED CD8+ CELLS IN FOLLICULAR LYMPHOMA WITH HIGH REACTIVATION POTENTIAL
EHA Learning Center, Theodora Anagnostou, 215683
ENZYME-FREE DIGITAL COUNTING OF ENDOGENOUS CIRCULAR RNA MOLECULES IN FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUES FROM PATIENTS WITH B-CELL MALIGNANCIES
EHA Learning Center, Mette Dahl, 215684
PROTEIN KINASE CK1 ΑLPHA SUSTAINS MANTLE CELL LYMPHOMA SURVIVAL BY IMPINGING ON BCR-LINKED SIGNALING PATHWAYS
EHA Learning Center, Sabrina Manni, 215685
WEE1 INHIBITION ENHANCES ANTI-APOPTOTIC DEPENDENCY OF DIFFUSE LARGE B-CELL LYMPHOMA CAUSED BY CELL CYCLE ARREST AND DNA DAMAGE INDUCTION
EHA Learning Center, Mathilde de Jong, 215686
INFLUENCE OF PLASMA EBV LOAD ON PROGNOSIS OF HIV-RELATED LYMPHOMAS
EHA Learning Center, Jose-Tomas Navarro, 215687
NUCLEOLIN ENHANCED ADRIAMYCIN RESISTANCE VIA THE REGULATION OF BCL-2 EXPRESSION IN CA46 BURKITT’S LYMPHOMA CELLS
EHA Learning Center, Jianda Hu, 215688
DOMINANT CYTOTOXIC NK CELL SUBSET WITHIN CLPD-NK PATIENTS IDENTIFIES A MORE AGGRESSIVE NK CELL PROLIFERATION
EHA Learning Center, Gregorio Barilà, 215689
IMMUNOPROFILING OF HIV-ASSOCIATED LYMPHADENOPATHY: HIGH-THROUGHPUT ANALYSIS OF THE T CELL RECEPTOR GENE REPERTOIRE SUPPORTS EPITOPE-SPECIFIC T CELL RESPONSES
EHA Learning Center, Evangelia Stalika, 215690
SUPERIORITY OF AVATROMBOPAG TO PLACEBO IN I REDUCING PLATELET TRANSFUSIONS IN PATIENTS WITH THROMBOCYTOPENIA AND CHRONIC LIVER DISEASE UNDERGOING SCHEDULED PROCEDURES- POOLED ANALYSIS OF 2 STUDIES
EHA Learning Center, Kavita aggarwal, 215691
PREDICTIVE FACTORS FOR DEVELOPING SYSTEMIC LUPUS ERYTHEMATOSUS AFTER CHILDHOOD AUTOIMMUNE CYTOPENIA
EHA Learning Center, Nathalie Aladjidi, 215693
THE POLYMORPHISM OF CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 9 GENE MAY CONTRIBUTE TO RISK OF IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Zi Sheng, 215694
FEATURES OF PRN1008, A BRUTON’S TYROSINE KINASE INHIBITOR, IN CLINICAL DEVELOPMENT FOR IMMUNE THROMBOCYTOPENIC PURPURA
EHA Learning Center, Steven Gourlay, 215695
ATRA CORRECTS IMPAIRED MACROPHAGE FUNCTION IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA THROUGH A20/NLRP3 SIGNALING PATHWAY
EHA Learning Center, Yun He, 215696
RH-TPO RESTORES MEGAKARYOCYTES AND BONE MARROW NICHE COMPONENTS IN THE TREATMENT OF SEVERE THROMBOCYTOPENIA IN PATIENTS WITH CIRRHOSIS ASSOCIATED WITH HEPATITIS B
EHA Learning Center, Wan-Yi Zhai, 215697
A HIGH-THROUGHPUT SCREENING ASSAY TO EVALUATE CHEMOTHERAPY-INDUCED MYELOSUPPRESSION USING HEALTHY PERIPHERAL BLOOD AND BONE MARROW
EHA Learning Center, Dimitrios Tsallos, 215698
A NOVEL ACQUIRED RUNX1 VARIANT IS RESPONSIBLE FOR ANKRD26 DYSREGULATION AND THROMBOCYTOPENIA IN SPORADIC FORM OF MYELODYSPLASTIC SYNDROME
EHA Learning Center, Fabrizio vianello, 215699
FACTORS AFFECTING THROMBOPOIETIN RECEPTOR AGONIST REINITIATION AFTER DISCONTINUATION IN WELL-CONTROLLED PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE UK: RESULTS FROM A MODIFIED DELPHI CONSENSUS PANEL
EHA Learning Center, Anuja Roy, 215700
IMMATURE PLATELET FRACTION (IPF): AN INTERESTING TOOL TO INVESTIGATE THROMBOCYTOPENIA
EHA Learning Center, Zoe Van de Wyngaert, 215701
INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISM IN EGYPTIAN CHILDREN AND ADOLESCENTS WITH IMMUNE THROMBOCYTOPENIA: ASSOCIATION WITH DISEASE SUSCEPTIBILITY, RESPONSE TO THERAPY AND OUTCOME
EHA Learning Center, Mohammed Mostafa Kamel Al-tawil, 215702
CLINICAL CHARACTERISTICS AND TREATMENT COURSES FOR CYTOMEGALOVIRUS-ASSOCIATED THROMBOCYTOPENIA IN IMMUNOCOMPETENT CHILDREN AFTER NEONATAL PERIOD
EHA Learning Center, Ye Jee Shim, 215703
RAISED EXPRESSION OF APRIL IN THE PLATELET WITH IMMUNE THROMBOCYTOPENIA AND ITS CLINICAL IMPLICATIONS
EHA Learning Center, Yunfeng Hao, 215704
EVALUATION OF HIT SYNDROME WITH AN AUTOMATED IMMUNOASSAY IN CORRELATION WITH THE 4T SCORE IN CARDIOVASCULAR PATIENTS
EHA Learning Center, Theoni Kanellopoulou, 215705
IMMATURE PLATELET FRACTION AS A MARKER OF THROMBOPOIESIS IN THROMBOCYTOPENIC PATIENTS
EHA Learning Center, David J Camilleri, 215706
CHANGES IN PLATELET AGGREGATION DURING PREGNANCY AND THE IMMEDIATE POSTPARTUM PERIOD
EHA Learning Center, Brwa Hussein, 215707
CHANGING PROFILE OF PLATELET ACTIVITY AND TURNOVER INDICES DURING TREATMENT RESPONSE OF IMMUNE THROMBOCYTOPENIA: PREDICATIVE VALUE OF REPONSE BY GLYCOCALICIN AND SOLUBLE CD40 LIGAND
EHA Learning Center, Hung Chang, 215708
THE IMPACT OF HIGH MOBILITY GROUP BOX 1 IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPENIA
EHA Learning Center, Mehmet Baysal, 215709
WHAT ARE THE UNDERLYING CAUSES AND CLINICAL CHARACTERISTICS OF CHILDREN WITH REACTIVE THROMBOCYTOSIS AT A KOREAN TERTIARY MEDICAL CENTER?
EHA Learning Center, Ye Jee Shim, 215710
STUDIES ON PLATELET FUNCTION IN A GROUP OF CLL PATIENTS DURING THE FIRST YEAR OF IBRUTINIB TREATMENT
EHA Learning Center, Bozena Sokolowska, 215712
VALIDATION OF THE PLASMIC SCORE FOR THROMBOTIC MICROANGIOPATIES IN A SINGLE UNVERSITY HOSPITAL
EHA Learning Center, Maria del Carmen Ballester Ruiz, 215713
OCCURRENCE AND MANAGEMENT OF HEPATOBILIARY ADVERSE EVENTS (AES) IN ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING LONG-TERM TREATMENT WITH ELTROMBOPAG: RESULTS FROM THE EXTEND STUDY
EHA Learning Center, Abderrahim Khelif, 215714
BENEFIT OF EARLY TREATMENT WITH BLINATUMOMAB: LONG-TERM SURVIVAL OUTCOMES FOR ADULT PATIENTS WITH RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA RECEIVING FIRST VS SUBSEQUENT SALVAGE THERAPY
EHA Learning Center, Franziska Severin, 215715
HEALTH-RELATED QUALITY OF LIFE AND RATES OF EMERGENCY ROOM VISITS AND HOSPITALIZATION IN PATIENTS WITH AL AMYLOIDOSIS: A PROSPECTIVE ANALYSIS
EHA Learning Center, Tiffany Quock, 215716
COST COMPARISON OF TREATMENT STRATEGIES FOLLOWING INITIATION WITH RD VERSUS VMP PLUS DARATUMUMAB IN NEWLY DIAGNOSED PATIENTS INELIGIBLE FOR ASCT
EHA Learning Center, Graham Jackson, 215717
IMPROVABLE LIFESTYLE FACTORS IN LYMPHOMA SURVIVORS
EHA Learning Center, Carla Minoia, 215718
QUALITY OF LIFE IN ADVANCED-STAGE,ASYMPTOMATIC,NON-BULKY FOLLICULAR LYMPHOMA TREATED WITH RITUXIMAB SHOWS SIGNIFICANT IMPROVEMENT COMPARED WITH WATCHFUL-WAITING: PHASE 3 RANDOMISED INTERNATIONAL STUDY
EHA Learning Center, Maria A V Marzolini, 215719
HOW TO IDENTIFY PATIENTS WITH MALIGNANT HEMOPATHIES WHO DON’T BENEFIT FROM STANDARD DOSE CHEMOTHERAPY
EHA Learning Center, Stéphanie Dubruille, 215720
THE ROLE OF MENTAL AND BEHAVIORAL DISORDERS IN LEUKEMIA PREDISPOSITION: A NATIONWIDE CASE-CONTROL STUDY
EHA Learning Center, Hanna Moisander-Joyce, 215721
IMPACT OF CMV PROPHYLAXIS ON RATES OF REHOSPITALIZATION IN ADULT CMV SEROPOSITIVE ALLOGENEIC HSCT RECIPIENT: EXPERIENCE FROM THE LETERMOVIR PHASE 3 CLINICAL TRIAL
EHA Learning Center, Jonathan SCHELFHOUT, 215722
QUALITY OF LIFE IN PATIENTS WITH RARE HEREDITARY HEMOLYTIC ANEMIA, THE IMPORTANCE OF SOCIAL SUPPORT
EHA Learning Center, Stephanie van Straaten, 215723
HOW PHYSICIANS' AND PATIENTS' CHARACTERISTICS AFFECT THE LENGTH OF PATIENTS' VISIT IN THE HEMATO-ONCOLOGICAL CLINIC.
EHA Learning Center, IRINA AMITAI, 215724
SYSTEMATIC REVIEWS OF ECONOMIC BURDEN AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PATIENTS WITH ACUTE MYELOID LEUKAEMIA (AML)
EHA Learning Center, Rachel Bosshard, 215725
VENETOCLAX IMPROVES QUALITY OF LIFE FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Tara Cochrane, 215726
NO ASSOCIATION BETWEEN INDOOR RADON AND CHILDHOOD LEUKEMIA IN FRECCLE (FINNISH REGISTER-BASED CASE-CONTROL STUDY OF CHILDHOOD LEUKEMIA)
EHA Learning Center, Atte Nikkilä, 215727
CLARITHROMYCIN ADDED TO THE VCD REGIMEN CAUSES REDUCED HEALTH-RELATED QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS
EHA Learning Center, Lene Kongsgaard Nielsen, 215728
RELINF PROJECT: PROSPECTIVE EPIDEMIOLOGICAL REGISTRY OF LYMPHOID NEOPLASMS IN SPAIN, ON BEHALF OF GELTAMO GROUP
EHA Learning Center, M Bastos Oreiro, 215729
A HEALTH STATE UTILITY MODEL ESTIMATING THE IMPACT OF IVOSIDENIB ON QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Michael Storm, 215730
ASSESSMENT OF ADHERENCE IN HAEMOPHILIA PATIENTS - EVALUATION OF AN US INSTRUMENT AND DEVELOPMENT OF A NEW QUESTIONNAIRE FOR USE IN GERMANY
EHA Learning Center, Sylvia von Mackensen, 215731
HEALTH-RELATED QUALITY OF LIFE (HRQOL) IN PEDIATRIC PATIENTS WITH RED CELL PYRUVATE KINASE DEFICIENCY
EHA Learning Center, Paraskevi Klothaki, 215732
QUALITY OF LIFE IS REDUCED IN PATIENTS WITH (SUSPECTED) PLATELET FUNCTION DISORDERS
EHA Learning Center, Maaike Blaauwgeers, 215733
PALLIATIVE CARE INDICATION IN ONCOHEMATOLOGIC PATIENTS: A COMPARISON TO SOLID TUMOR PATIENTS
EHA Learning Center, Lucia Morais, 215734
COST PER MEDIAN MONTH OF PROGRESSION‐FREE SURVIVAL FOR DARATUMUMAB PLUS BORTEZOMIB AND DEXAMETHASONE COMPARED WITH CARFILZOMIB PLUS DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Eric Maiese, 215735
EFFICACY AND SAFETY OF FACILITATED SUBCUTANEOUS IGG ADMINISTRATION IN PATIENTS WITH SECONDARY IMMUNODEFICIENCY DUE TO HEMATOLOGICAL MALIGNANCIES. A SINGLE-CENTER RETROSPECTIVE ANALYSIS.
EHA Learning Center, Maria Dimou, 215736
IMPACT OF LOW GRADE ADVERSE EVENTS OF TYROSINE KINASE INHIBITORS ON THE QUALITY OF LIFE OF PATIENTS TREATED FOR CHRONIC MYELOID LEUKEMIA
EHA Learning Center, Benlazar Sidi Mohamed El Amine, 215737
HEME-INDUCIBLE LIPID OXIDATION PATTERN SUPPORTS MONITORING OF CELL-FREE HEMOGLOBIN ACTIVITY IN PATIENTS WITH SICKLE CELL DISEASE.
EHA Learning Center, Jeremy Deuel, 215738
COMPLEMENT ACTIVATION IN HOMOZYGOUS SICKLE CELL DISEASE PATIENTS IS MODULATED BY HYDROXYUREA
EHA Learning Center, Lubka Roumenina, 215739
EARLY RECOGNITION OF THE SICKLING PROCESS OF ERYTHROCYTES BY LABEL-FREE LIGHT MICROSCOPIC IMAGING IN PATIENTS WITH SICKLE CELL DISEASE
EHA Learning Center, Irene Lorand Metze, 215741
SICKLE CELL DISEASE SEVERITY MEASURE: DEVELOPMENT, TRANSLATION, AND PATIENT CULTURAL SENSITIVITY VALIDATION
EHA Learning Center, Kenneth Bridges, 215742
IMPROVEMENT OF THE MULTIDISCIPLINARY MANAGEMENT OF SICKLE CELL DISEASE PATIENTS: IMPLEMENTATION OF A SICKLE CELL DISEASE PATIENT’S CLINICAL DATABASE: BELGIAN REGISTER OF SICKLE CELL DISEASE PATIENTS
EHA Learning Center, Beatrice Gulbis, 215743
VARIATIONS IN COMPLICATIONS RELATED TO VASO-OCCLUSIVE CRISES AND HYDROXYUREA USE IN PATIENTS WITH SICKLE CELL DISEASE: OBSERVATIONS FROM STUDIES IN THE USA, SPAIN AND THE GULF REGION
EHA Learning Center, Elena Cela, 215744
CORRELATION BETWEEN HEMOLYSIS AND HYPERCOAGULABILITY MARKERS AND EFFECTS OF HYDROXYUREA THERAPY IN SICKLE CELL PATIENTS
EHA Learning Center, Maria de Fátima Sonati, 215745
INFLUENCE OF BCL11A POLYMORPHYSMS ON FETAL HEMOGLOBIN LEVELS AND HAEMOLYSIS MARKERS IN SICKLE CELL ANEMIA PEDIATRIC PATIENTS NOT RECEIVING HYDROXYUREA
EHA Learning Center, Dalila Luciola ZANETTE, 215746
TICAGRELOR VERSUS PLACEBO FOR THE REDUCTION OF VASO-OCCLUSIVE CRISES IN PEDIATRIC SICKLE CELL DISEASE: DESIGN OF A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER PHASE 3 STUDY (HESTIA3)
EHA Learning Center, Matthew Heeney, 215747
NOVEL TRIAL DESIGN TO EVALUATE ORAL VOXELOTOR FOR THE TREATMENT OF SICKLE CELL DISEASE: THE PHASE 3 HEMOGLOBIN OXYGEN AFFINITY MODULATION TO INHIBIT SICKLE HEMOGLOBIN POLYMERIZATION (HOPE) TRIAL
EHA Learning Center, Kenneth I. Ataga, 215748
OUTCOME OF PHILADELPHIA CHROMOSOME-POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS RECEIVING TYROSINE KINASE INHIBITOR MAINTENANCE THERAPY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
EHA Learning Center, Tuija Tapaninen, 215749
PD-1 OVEREXPRESSION ON BONE MARROW RESIDENT CD8+ MEMORY T-CELL SUBSETS COULD BE A PREDICTABLE MARKER FOR LEUKEMIA RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION.
EHA Learning Center, Mikhail Drokov, 215750
OUTCOME OF SECOND SOLID CANCER AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION: A COHORT STUDY ON 4065 PATIENTS ON BEHALF OF THE COMPLICATIONS AND QUALITY OF LIFE WORKING PARTY OF THE EBMT
EHA Learning Center, André Tichelli, 215751
SIMILAR OUTCOMES OF REDUCED INTENSITY HAPLOIDENTICAL TRANSPLANTATION WHEN COMPARED TO MATCHED UNRELATED DONOR TRANSPLANT IN DIFFUSE LARGE B CELL LYMPHOMA. A JOINT ANALYSIS FROM CIBMTR-LC & EBMT-LWP.
EHA Learning Center, Anna Sureda, 215752

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings